Delivery Order SPE2DR25D2206-SPE2DR26F9ND5
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on January 20, 2026, for the supply of Venclexta 50 mg tablets in unit dose packages of seven at a firm fixed price of $2,611.32. This non-set-aside, competitively awarded delivery order is scheduled for completion by February 10, 2026, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (28-count units) with a ceiling value of $4,825.98. This firm fixed-price delivery order, issued on December 11, 2025, is scheduled for completion by January 5, 2026, and carries no set-aside designation. The award represents a competitive procurement under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), valued at...
- On January 23, 2026, the Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Venclexta 100 mg tablets (120 count) with a ceiling value of $10.4K. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively to support federal medical procurement needs. The contract's place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of February 13, 2026. This delivery order is...
- On January 16, 2026, the Defense Logistics Agency awarded a delivery order valued at $2,418.13 to AmerisourceBergen Drug Corp for the supply of VENCLEXTA 100 MG tablets (28-count unit of use packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of February 9, 2026. The awardee, AmerisourceBergen Drug Corp, is a subsidiary of Cencora, Inc., one of the nation's largest pharmaceutical distributors, with its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (120-count units) valued at $12,463.22 on October 30, 2025, with an ultimate completion date of November 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VENCLEXTA 100 mg tablets (120 count) on November 17, 2025, valued at $10,251.99 with firm fixed pricing and an ultimate completion date of December 9, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Venclexta 100 mg tablets (120 count) at a ceiling value of $9,728.17. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is set for ultimate completion by May 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Venclexta 100 mg tablets in quantities of 28 units. This firm fixed-price delivery order, valued at $2,412.99, is non-set-aside and competitively awarded, with an ultimate completion date of December 5, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate operations as a major...
- The Defense Logistics Agency awarded a delivery order valued at $2,418.13 to AmerisourceBergen Drug Corp for the supply of VENCLEXTA 100 mg tablets (28-count units) on January 16, 2026, with an ultimate completion date of February 9, 2026. This firm fixed-price delivery order was competitively awarded without set-aside designation and is performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Venclexta 100 mg tablets (120-count units) valued at $9,728.17, with an ultimate completion date of December 1, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9ND5Delivery Order
This delivery order, awarded on January 27, 2026, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, covers the supply of VENCLEXTA 50 MG tablets in unit-dose packaging of seven tablets, with a ceiling value of $1,305.66 and a firm fixed-price structure. The award is not set-aside and represents a competitive procurement under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999.00 vehicle established through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving critical federal medical procurement needs for military and veteran healthcare systems. The parent company, Cencora, Inc. (doing business as AmerisourceBergen), maintains an additional substantial IDC with the DLA valued at up to $999,999,999.00 through December 31, 2031, demonstrating the company's long-standing role in supporting the Department of Defense's pharmaceutical supply chain. This procurement exemplifies the DLA's reliance on prime pharmaceutical vendors to deliver specialty medications to military treatment facilities and healthcare programs worldwide. VENCLEXTA is an oncology medication used in the treatment of certain blood cancers, reflecting the DLA's need for comprehensive access to brand-name pharmaceuticals across multiple therapeutic domains. The delivery order maintains the firm fixed-price structure typical of DLA pharmaceutical procurement, with performance required by February 18, 2026, ensuring timely supply of critical medications to federal healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 1/26/26 |